Featured articles from the journal CHEST®, December 2022
Glenview, Illnois | December 15, 2022
Published monthly, the journal CHEST(opens in new tab/window)® features peer-reviewed, cutting-edge original research in chest medicine: Pulmonary, critical care and sleep medicine and related disciplines. Journal topics include asthma, chest infections, COPD, critical care, diffuse lung disease, education and clinical practice, pulmonary vascular disease, sleep, thoracic oncology and the humanities.
The December issue(opens in new tab/window) of CHEST contains 36 articles, including clinically relevant research, reviews, case series, commentary and more. Each month, the journal also offers complementary web and multimedia activities(opens in new tab/window), including visual abstracts, to expand the reach of its most interesting, timely and relevant research.
“Well-suited for the final issue of 2022, the December issue of the journal CHEST includes articles that look back at lessons learned from the COVID-19 pandemic and insights into planning for future surges,” says Editor-in-Chief of the journal CHEST, Peter Mazzone, MD, MPH, FCCP. “’COVID-19: Lessons Learned, Lessons Unlearned, Lessons for the Future(opens in new tab/window)’ was written by editorial board members for the critical care section of the journal CHEST and ‘A Regional Command Center for Pandemic Surge(opens in new tab/window)’ is a prospective observational study conducted in Catalonia from March 15, 2020, to July 1, 2021.”
Also included in the current issue of the journal CHEST:
Recommending constant microbiological surveillance, “Multidrug-Resistant and Extended-Spectrum β-Lactamase Gram-Negative Bacteria in Bilateral Lung Transplant Recipients(opens in new tab/window)” discourages the use of empirical broad-spectrum antibiotics.
A large, multicenter retrospective study, “Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure(opens in new tab/window)” finds large variation in the use of inhaled nitric oxide and inhaled epoprostenol during acute respiratory failure across the United States. A visual abstract for the research can be viewed here(opens in new tab/window).
Diffuse Lung Disease
Looking at patients with lymphangioleiomyomatosis, “Impact of Age, Menopause, and Sirolimus on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis(opens in new tab/window)” research finds increasing age and menopausal status are associated with a reduced risk of development of spontaneous pneumothoraces (SP), and the use of mechanistic target of rapamycin inhibitors is associated with reduced recurrence risk of SP. A visual abstract for the research can be viewed here(opens in new tab/window).
The largest study to date on the topic, “Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection(opens in new tab/window)” shows that, aside from specific scenarios, safety or risk of bleeding alone should no longer be a deterrent to the use of intrapleural fibrinolytic and enzyme therapy in pleural infection. A visual abstract for the research can be viewed here(opens in new tab/window).
Notes for editors
To view the entire December issue of CHEST journal (volume 162, issue 6), published by Elsevier(opens in new tab/window), visit journal.chestnet.org(opens in new tab/window) and follow @journal_CHEST(opens in new tab/window) on Twitter for the latest journal news.
Full text of these articles and interviews with the authors are available to credentialed journalists upon request; contact Laura DiMasi, PR and Communications Specialist, American College of Chest Physicians (CHEST), at [email protected](opens in new tab/window).
About the journal CHEST®
The journal CHEST(opens in new tab/window), the official publication of the American College of Chest Physicians®, features the best in peer-reviewed, cutting-edge original research in the multidisciplinary specialties of chest medicine: pulmonary, critical care, and sleep medicine; thoracic surgery; cardiorespiratory interactions; and related disciplines. Published since 1935, it is home to the highly regarded clinical practice guidelines and consensus statements. Access the journal CHEST online at journal.chestnet.org(opens in new tab/window).
About the American College of Chest Physicians
The American College of Chest Physicians® (CHEST) is the global leader in the prevention, diagnosis, and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication, and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST®, visit chestnet.org.(opens in new tab/window)
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses.
Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, medical education, and nursing education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet(opens in new tab/window) and Cell(opens in new tab/window); 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation(opens in new tab/window) and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX(opens in new tab/window), a global provider of information-based analytics and decision tools for professional and business customers.